SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1021 335X "

Sökning: L773:1021 335X

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Andersson, Ken G, et al. (författare)
  • Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors
  • 2015
  • Ingår i: Oncology Reports. - Spandidos Publications. - 1021-335X .- 1791-2431. ; 34:2, s. 1042-8
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Expression of human epidermal growth factor receptor type 3 (HER3) in malignant tumors has been associated with resistance to a variety of anticancer therapies. Several anti-HER3 monoclonal antibodies are currently under pre-clinical and clinical development aiming to overcome HER3-mediated resistance. Radionuclide molecular imaging of HER3 expression may improve treatment by allowing the selection of suitable patients for HER3-targeted therapy. Affibody molecules are a class of small (7kDa) high-affinity targeting proteins with appreciable potential as molecular imaging probes. In a recent study, we selected affibody molecules with affinity to HER3 at a low picomolar range. The aim of the present study was to develop an anti-HER3 affibody molecule suitable for labeling with radiometals. The HEHEHE-Z08698-NOTA and HEHEHE-Z08699-NOTA HER3-specific affibody molecules were labeled with indium‑111 (111In) and assessed invitro and invivo for imaging properties using single photon emission computed tomography (SPECT). Labeling of HEHEHE-Z08698-NOTA and HEHEHE-Z08699-NOTA with 111In provided stable conjugates. Invitro cell tests demonstrated specific binding of the two conjugates to HER3-expressing BT‑474 breast carcinoma cells. In mice bearing BT‑474 xenografts, the tumor uptake of the two conjugates was receptor‑specific. Direct invivo comparison of 111In-HEHEHE-Z08698-NOTA and 111In-HEHEHE-Z08699‑NOTA demonstrated that the two conjugates provided equal radioactivity uptake in tumors, although the tumor-to-blood ratio was improved for 111In-HEHEHE-Z08698-NOTA [12±3 vs. 8±1, 4h post injection (p.i.)] due to more efficient blood clearance. 111In-HEHEHE-Z08698-NOTA is a promising candidate for imaging of HER3-expression in malignant tumors using SPECT. Results of the present study indicate that this conjugate could be used for patient stratification for anti-HER3 therapy.</p>
  •  
3.
  • Andersson, Ken G., et al. (författare)
  • Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors
  • 2015
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 34:2, s. 1042-1048
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Expression of human epidermal growth factor receptor type 3 (HER3) in malignant tumors has been associated with resistance to a variety of anticancer therapies. Several anti-HER3 monoclonal antibodies are currently under pre-clinical and clinical development aiming to overcome HER3-mediated resistance. Radionuclide molecular imaging of HER3 expression may improve treatment by allowing the selection of suitable patients for HER3-targeted therapy. Affibody molecules are a class of small (7 kDa) high-affinity targeting proteins with appreciable potential as molecular imaging probes. In a recent study, we selected affibody molecules with affinity to HER3 at a low picomolar range. The aim of the present study was to develop an anti-HER3 affibody molecule suitable for labeling with radiometals. The HEHEHE-Z08698-NOTA and HEHEHE-Z08699-NOTA HER3-specific affibody molecules were labeled with indium-111 (In-111) and assessed in vitro and in vivo for imaging properties using single photon emission computed tomography (SPECT). Labeling of HEHEHE-Z08698-NOTA and HEHEHE-Z08699-NOTA with In-111 provided stable conjugates. In vitro cell tests demonstrated specific binding of the two conjugates to HER3-expressing BT-474 breast carcinoma cells. In mice bearing BT-474 xenografts, the tumor uptake of the two conjugates was receptor-specific. Direct in vivo comparison of In-111-HEHEHE-Z08698-NOTA and In-111-HEHEHE-Z08699-NOTA demonstrated that the two conjugates provided equal radioactivity uptake in tumors, although the tumor-to-blood ratio was improved for In-111-HEHEHE-Z08698-NOTA [12 +/- 3 vs. 8 +/- 1,4 h post injection (p.i)] due to more efficient blood clearance. In-111-HEHEHE-Z08698-NOTA is a promising candidate for imaging of HER3-expression in malignant tumors using SPECT. Results of the present study indicate that this conjugate could be used for patient stratification for anti-HER3 therapy.</p>
  •  
4.
  •  
5.
  • Andreasen, S., et al. (författare)
  • Genomic profiling of a combined large cell neuroendocrine carcinoma of the submandibular gland
  • 2016
  • Ingår i: Oncology Reports. - 1021-335X. ; 35:4, s. 2177-2182
  • Tidskriftsartikel (refereegranskat)abstract
    • A 69-year-old female with no previous medical history presented with a rapidly growing submandibular mass. Fine needle aspiration cytology suggested a small-cell carcinoma and PET-CT showed increased 18-FDG uptake in the submandibular mass as well as in a lung mass. Submandibular resection and selective neck dissection was performed and histopathologic examination revealed a combined large-cell neuroendocrine carcinoma (LCNEC) with a squamous component and without lymph node metastases. Resection of the lung tumor revealed a papillary adenocarcinoma that was morphologically distinctly different from the LCNEC. The patient died of her lung cancer after 19 months without evidence of recurrence of the LCNEC. Genomic profiling of the salivary gland LCNEC revealed a hypodiploid genome predominated by losses of whole chromosomes or chromosome arms involving chromosomes 3p, 4, 7q, 10, 11, 13, 16q and gains of 3q and 16p. In addition, there was a segmental gain of 9p23-p22.3 including the NFIB oncogene. Continued studies of salivary gland LCNEC may provide new knowledge concerning potential diagnostic biomarkers and may ultimately also lead to the identification of new treatment targets for patients with these aggressive carcinomas.
  •  
6.
  • Argyropoulos, C., et al. (författare)
  • Operational criteria for selecting a cDNA microarray data normalization algorithm
  • 2006
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 15:4, s. 983-996
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Microarray technology allows gene expression profiling at a global level. Many algorithms for the normalization of raw microarray data have been proposed, but no attempt has yet been made to propose operationally verifiable criteria for their comparative evaluation, which is necessary for the selection of the most appropriate method for a given dataset. This study develops a set of operational criteria for assessing the impact of various normalization algorithms in terms of accuracy (bias), precision (variance) and over-fitting (information reduction). The use of these criteria is illustrated by applying the three most widely used algorithms (global median normalization, spiked-in based normalization and lowess) on a specifically designed, multiply-controlled dataset.</p>
  •  
7.
  • Arlehag, L, et al. (författare)
  • ATM expression in rectal cancers with or without preoperative radiotherapy
  • 2005
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 14:2, s. 313-317
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Patients with ATM (Ataxia-Telangiectasia mutated) mutation show increased sensitivity to radiation and have a higher risk of developing malignancies. The present study aimed to investigate whether ATM expression was related to radiotherapy, and clinicopathological and biological variables in rectal cancers. ATM expression was immunohistochemically examined in 78 rectal cancers from patients who participated in a Swedish rectal cancer trial of preoperative radiotherapy. Of 78 patients, 44 underwent surgery alone, and 34 underwent both preoperative radiotherapy and surgery. Fifty-eight cases had normal rectal mucosa adjacent to the tumour. The results showed that, compared to normal mucosa, tumours had less nuclear (p=0.03) but more cytoplasmic expression of ATM (p=0.004). In tumours, less expression of ATM, either in the nucleus (p=0.07) or in the cytoplasm (p=0.02 for staining intensity, and p=0.07 for staining percentage), tended to be correlated with male patients. Also, ATM expression was not related to radiotherapy or other clinicopathological and biological variables (p &gt; 0.05). In conclusion, the pattern of ATM expression was changed from normal mucosa to tumour. Less expression of ATM may be related to males.</p>
  •  
8.
  • Armakolas, Athanasios, et al. (författare)
  • Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients
  • 2012
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 28:6, s. 2255-2263
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Gene expression patterns as well as gene interactions are under investigation for their involvement in tumour heterogeneity. The molecular classification of breast cancer based on hormone receptor expression, grade and HER2 receptor levels, is indicative but not adequate enough to complete the prognostic data. The objectives of this study were to validate the prognostic value of 19 genes, solely, and as parts of classifiers (sets of genes), in breast cancer patients and to determine whether the expression of these genes and classifiers is correlated with breast cancer molecular classification. Gene expression was examined in the blood of 88 breast cancer patients and 50 healthy controls using multiplex quantitative real-time PCR. Patients with a second primary malignancy showed a statistically significant difference when compared with: i) patients with a single breast cancer, for an 8-gene classifier (p&lt;0.02); and ii) healthy individuals (classifier FBX033, FLJ339115) (p&lt;0.01), with respect to gene expression. The classifier ENY2, USP38 was associated with the development of primary breast cancer. A newly established classifier (ENY2, USP38, RPS7, Osbpl-1 and ETF1) indicated a statistically significant association with HER2 subtype patients, compared to patients with a different molecular classification (p&lt;0.04). The gene FLJ33915 was differentially expressed in a subgroup of HER2-positive patients with infiltrated axillary lymph nodes (p&lt;0.028). We validated the prognostic value of 4 classifiers for primary and second primary malignancy. Evidence of a classifier predicting the HER2 subtype and the gene FLJ33915 which subdivides HER2 subtype patients is also presented.</p>
  •  
9.
  •  
10.
  • Babaei, Mohammad Hossein, et al. (författare)
  • [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo : preparation and pre-clinical evaluation
  • 2005
  • Ingår i: Oncology Reports. - 1021-335X .- 1791-2431. ; 13:6, s. 1169-75
  • Tidskriftsartikel (refereegranskat)abstract
    • <p>Expression of epidermal growth factor receptors (EGFR) has prognostic and predictive value in many kinds of tumors. Imaging of expression of EGFR in vivo may give valuable diagnostic information. The epidermal growth factor (EGF), a natural ligand, is a possible candidate for the targeting of EGFR. The present study describes a method for preparation of (99m)Tc-EGF via the hydrazinopyridine-3-carboxylic acid (HYNIC) conjugation using tricine and ethylenediamine-N,N'-diacetic acid (EDDA) as co-ligands. Both conjugates bound EGFR expressing cells with nanomolar affinity, and demonstrated good intracellular retention. The complex with EDDA demonstrated much higher stability in blood serum and during cysteine challenge. Biodistribution of (99m)Tc-EDDA-HYNIC-EGF in normal mice demonstrated fast blood clearance of conjugate, and its ability to bind EGFR in vivo. (99m)Tc-EDDA-HYNIC-EGF is a promising candidate for visualization of EGFR expression in vivo.</p>
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (7)
Typ av publikation
tidskriftsartikel (117)
Typ av innehåll
refereegranskat (117)
övrigt vetenskapligt (1)
Författare/redaktör
Tolmachev, Vladimir, (9)
Orlova, Anna, (7)
Glimelius, Bengt, (6)
Sun, Xiao-Feng, 1959 ... (6)
Wågsäter, Dick, (6)
Zhang, Hong, 1957-, (5)
visa fler...
Lindblom, Annika (4)
Lennernäs, Bo, 1963- ... (4)
Melin, Beatrice, (4)
Zhang, Hong, (4)
Lundqvist, Hans (3)
Eriksson, M, (3)
Glimelius, B, (3)
Ståhl, Stefan, (3)
Skoog, L, (3)
Rosestedt, Maria, (3)
Stål, Olle, (2)
Nilsson, Per J. (2)
Kaaks, Rudolf (2)
Nilsson, S (2)
Nilsson, Torbjörn K (2)
Eriksson, Mikael, (2)
Jansson, Agneta, 197 ... (2)
Andersson, S (2)
Farnebo, Lovisa, (2)
Stahl, S (2)
Linder, S, (2)
Nygren, Peter, (2)
Fornander, Tommy, (2)
Gedda, Lars, (2)
Sandström, Mattias, (2)
Tidefelt, Ulf, (2)
Nordenskjöld, Bo, (2)
Hardell, Lennart (2)
Heegaard, S (2)
Schedvins, K (2)
Albertsson, Per, 196 ... (2)
Palmqvist, Richard, (2)
Paul, Christer, (2)
Rosell, Johan, (2)
Löfblom, John, (2)
Sandström, Per, (2)
Almqvist, Ylva, (2)
Varasteh, Zohreh (2)
Stenman, Göran, 1953 ... (2)
Sigurdardottir, S (2)
Löfgren, Sture, (2)
Rosdahl, Inger, 1943 ... (2)
Andersson, Ken G., (2)
Malm, Magdalena, (2)
visa färre...
Lärosäte
Linköpings universitet (30)
Karolinska Institutet (27)
Uppsala universitet (21)
Örebro universitet (11)
Göteborgs universitet (9)
Umeå universitet (9)
visa fler...
Lunds universitet (7)
Kungliga Tekniska Högskolan (3)
Högskolan i Jönköping (3)
Högskolan i Skövde (3)
visa färre...
Språk
Engelska (117)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (78)
Naturvetenskap (6)
Teknik (1)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy